# Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

> **NCT03991819** · PHASE1 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- Non-small Cell Carcinoma

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03991819
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-20
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991819, "Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03991819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*